Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 52Kidney Neoplasms 43Melanoma 23Neoplasm Metastasis 14Uterine Cervical Neoplasms 8Breast Neoplasms 5Vaginal Neoplasms 4Penile Neoplasms 4Pancreatic Neoplasms 4Oropharyngeal Neoplasms 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Anus Neoplasms 4Prostatic Neoplasms 3Ovarian Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Merkel Cell 3Vulvar Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Testicular Germ Cell Tumor 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Carcinoma, Hepatocellular 2Wilms Tumor 1

Interventions

pembrolizumab 3Nivolumab 3atezolizumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × aldesleukin × Genitourinary × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡